Actively Recruiting
Phase 3 Randomized, Double-Blind Study of KN3835 Versus Placebo for Treating Flexible and Semi-Flexible Hammertoe Evaluating Safety, Tolerability, and Effectiveness
Led by Endo USA Inc., a Keenova Therapeutics Company · Updated on 2026-09-14
554
Participants Needed
7
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy, safety, and tolerability of KN3835 compared to a placebo in treating flexible and semi-flexible hammertoe HMT. This Phase 3, randomized, double-blind study aims to better understand how the study drug affects this condition by measuring changes in toe flexion contracture and foot function among participants. Participants will be randomly assigned to receive either KN3835 or a matching placebo. The treatment period lasts up to 57 days, during which participants will receive the study drug or placebo under close monitoring. The study uses a quadruple-blind design to ensure unbiased results. Throughout the study, participants will undergo assessments including measurements of toe flexion contracture using a goniometer, evaluations of foot function through the Foot Function Index, and patient-reported scales such as the Patient Global Impression of Severity and Change. Safety is closely monitored by recording any treatment-emergent adverse events. The total participation duration aligns with the 57-day treatment and assessment period.
CONDITIONS
Brief Title
Study to Assess KN3835 in the Treatment of Flexible/Semi-Flexible Hammertoe (HMT)
Research Team
C
Clinical Operations
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here